Company / R&D Expense
Cocrystal Pharma, Inc. R&D Expense History
FY2012-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$8.8M
FY2021
5-year range
$489.3K / $8.8M
FY2017-FY2021
Trend
+119.6%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $5M to $9M over the past 2 years.
Based on SEC 10-K filings.
$9M in FY2021.
Improved from $5M to $9M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2021, r&d expense increased 119.6% year-over-year.
Company context
Key Data Points
- Altman Z-Score 14.87 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | $8.8M | +119.6% |
| FY2020 | $4.0M | -14.2% |
| FY2019 | $4.7M | +853.7% |
| FY2012 | $489.3K | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026